BPM Business Summary

Bio Preventive Medicine Corp. (BPM) is a clinical-stage biotechnology firm specializing in the development and commercialization of precision in vitro diagnostic (IVD) solutions for chronic diseases, primarily diabetic kidney disease (DKD). The company generates revenue through a multi-pronged model comprising the sale of its proprietary ELISA diagnostic kits, laboratory testing services, and strategic technology licensing to global partners, such as its recent MOU with Boditech Med. Its flagship product, DNlite-IVD103, utilizes the patented uPTM-FetA biomarker to predict progressive renal decline up to five years before clinical symptoms appear, offering a significant lead time over traditional creatinine-based assessments. BPM operates within a competitive landscape alongside specialized firms such as Renalytix and BioPorto, as well as diversified diagnostic giants like Abbott and Roche. The company distinguishes itself by focusing on early-stage preventive screening and risk stratification, positioning its technology as a leading solution for precision kidney health management in global clinical care guidelines. The company was founded in 2014 as a high-tech spin-off from Taiwan’s Industrial Technology Research Institute (ITRI) by Dr. Tzu-Ling (Karen) Tseng, who serves as the current CEO and Chairperson. Dr. Tseng brings over two decades of biomedical research expertise, having previously spearheaded the national biomarker research project at ITRI. The leadership team includes CFO Tsu Hsun (Jason) Kuo, who oversees financial strategy and investor relations. BPM is backed by a sophisticated investor base, including corporate directors from An Fu Capital (represented by Yeh Yu-Ying) and Yongwei Capital. The board’s pedigree is further strengthened by its origins within ITRI, ensuring a deep technical foundation in molecular diagnostics and a robust intellectual property portfolio of over 79 global patents.